A COMPARATIVE STUDY OF THE DURATION OF DRUG USE AMONG SUBSTANCE ABUSERS WITH PSYCHIATRIC SYMPTOMS
Keywords:
Substance abuse, Psychiatric symptoms, DurationAbstract
This is a descriptive study of substance users who were diagnosed with mental illness receiving treatment in government facilities, including 1,000 patients from 10 provinces nationwide and related persons with a total of 4,513 people. Data were collected through interviews and patient medical records. Data were analyzed using descriptive statistics and ANOVA.
The research findings revealed a demographic breakdown of the sample, with 93.0% being male, 20.0% falling into the youth category (under 24 years old), and 64.0% being single. Additionally, 43.5% were unemployed, 14.8% resided with an alcoholic, and 14.8% lived with another individual. Notably, 17.4% utilized drugs to manage irregularities, while 71.3% had relatives or close associates who were drug users. Moreover, 79.2% of the participants had undergone prior drug and psychiatric treatments. Psychiatric symptoms identified included paranoia, alongside other indicators of mental distress such as irritability, aggression, impulsivity, decreased restraint, hallucinations, delusions, and confusion, which could potentially lead to violent behavior. Among the sample group, 66.9% initiated drug use with amphetamines, with the earliest reported age of onset being 10 years old and the average age of initiation being 19 years. Presently, 73.9% predominantly use methamphetamine (YABA and ICE). Furthermore, 44.4% engaged in polydrug use, consuming multiple substances concurrently. Individuals experiencing drug-induced psychosis had an average duration of drug use of 12.5 years. Analysis based on the type of drug causing psychotic symptoms revealed differing durations of use; heroin users averaged 18.8 years of use, methamphetamine users averaged 12.4 years, and marijuana users averaged 15.7 years. Significantly varied durations of drug use were observed (P<0.0001).
Downloads
References
United Nations Office on Drugs and Crime (UNODC). World drug report 2019. Vienna: United Nations publication; 2019.
Merlin MD. Archaeological evidence for the tradition of psychoactive plant use in the old world. Economic Botany 2003; 57(3): 295-323.
Sullivan RJ, Hagen EH. Psychotropic substance-seeking: Evolutionary pathology or adaptation? Addiction 2002; 97(4): 389-400.
Department of Fine Arts. The “Tra Sam Duang” Laws. Bangkok: Veteran printing house; 1978.
Kanato M, Leyatikul P, Wonguppa R. Impacts of Medical Cannabis Law in Thailand. ONCB Journal 2020; 36(2): 27-36.
Poshyachinda V. Heroin in Thailand. in the 4th Anniversary of the Office of the Narcotics Control Board. Bangkok: Office of the Prime Minister; 1980. 56-87.
Poshyachinda V, Srisurapanont M, Perngparn U. Amphetamine type stimulants epidemic in Thailand: a country profile. In WHO meeting on amphetamine, MDMA, and other psycho stimulants phase II. Bangkok, Thailand; 1999. 22-26.
Poshyachinda V, Phittayanon P, Simasatitkul V, Perngparn U. Stimulant use, abuse, and dependence in Thailand. Alcohol and drugs perspectives, prevention and control-Asia Pacific region. Sri Lanka: Alcohol and Drug Information Centre; 1998. 77-106.
Wonguppa R, Kanato M. The prevalence and associated factors of new psychoactive substance use: A 2016 Thailand national household survey. Addict Behav Rep 2018; 7: 111-115
Kanato M, Leyatikul P, Wonguppa R. Cannabis Situation among the Thai Youth after Law Amendment. ONCB Journal 2022; 36(2): 27-36.
United Nations Office on Drugs and Crime (UNODC). World drug report 2023. Vienna: United Nations publication; 2023.
Kanato M, Sarasiri R, Leyatikul P, (Eds.). ASEAN DRUG MONITORING REPORT 2022. Bangkok: ASEAN Narcotics Cooperation Center; 2023.
Kanato M. Leyatikul P. Size Estimation of Substances Users Population in Thailand 2019. ONCB Journal 2020; 36(2): 37-48.
Office of Secretary of National Addiction treatment & Rehabilitation Committee, Ministry of Public Health. Statistics on Addiction Treatment & Rehabilitation [online] 2020 [cited 2024 March 7]. Available from: https://ncmc.moph.go.th/home/index/dash
WHO. Management of substance abuse [online] 2021 [cited 2021 Jan 21]. Available from: https://www. Who. int/substance_abuse/facts/ATS/en/
McCrady BS, Epstein EE. Addictions: A comprehensive guidebook. Oxford University Press; 2013.
Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine - associated psychosis. Journal of Neuroimmune Pharmacology 2012; 7(1): 113-139.
MacCallum RC, Widaman KF, Zhang S, Hong S. Sample size in factor analysis. Psychological methods 1999; 4(1): 84-99.
Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsycho pharmacology 2003. 6(4); 347-352.
Arunogiri S, Foulds JA, McKetin R, Lubman DI. A systematic review of risk factors for methamphetamine-associated psychosis. Australian & New Zealand Journal of Psychiatry 2018; 52(6): 514-529.
Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G. Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry 2012; 169(4): 389-396.
McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA psychiatry 2013; 70(3): 319-324.
Gan H, Zhao Y, Jiang H, Zhu Y, Chen T, Tan H, et al. A research of methamphetamine induced psychosis in 1,430 individuals with methamphetamine use disorder: clinical features and possible risk factors. Frontiers in Psychiatry 2018; 9: 1-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Community Health Development Quarterly Khon Kaen University

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."